Restricted, Non-Sensitive



# Market Access in MedTech

**Course Director:** Anh Bourcet (Nguyen), PhD

**Hwee Lin Wee** 

Saw Swee Hock School of Public Health,

**National University of Singapore** 

#### Programme – Day 1 – Mon 26 Feb 2024

TOPICS	Speakers
Welcome	
What is Market Access?	Anh Bourcet
HTA policies & evolution in APAC	SS Lee, Senior Director for Government Affairs and Market Access, Medtronic North Asia
Deep dive in Australia : Advocacy strategy to unlock access & funding	Michael Nobes Director, Market Access Abbott, Diabetes
Deep dive in Japan : Market Access strategy	Anh Bourcet
Group case work preparation	Anh Bourcet
Conclusion	

## Programme – Day 2 – Tue 27 Feb 2024

TOPICS	Speakers
Recap Day 1	
How to develop a Market Access Strategy for MedTech?	Anh Bourcet
Deep Dive in China - Market Access Strategy in a complex market	Edmund Shi Director, Market Access Head China, Johnson & Johnson MedTech
Policy Shaping & stakeholder engagement	Jamie Kebely Vice President for Asia-Pacific & Japan Government Affairs, Siemens Healthineers
Framework for Value Proposition How to differentiate your technology?	Anh Bourcet
Is Market Access for Medical Devices different from Pharmaceuticals?	TBC
Group case work	
Conclusion	

## Programme – Day 3 – Wed 28 Feb 2024

TOPICS	Speakers
Recap Day 2	
How to develop an Evidence Generation Strategy for Market Access ?	TBC
Demonstrating the economic value: key considerations in modelling for MedTech	Hwee-Lin Wee, Associate Professor, Saw Swee Hock School of Public Health, NUS
HTA in ASEAN: understanding what healthcare payers care about	Dr Yot Teerawattananon Co-Director MIDAS (Medical Innovation Development and Assessment Support), Visiting Professor NUS (National University of Singapore), Founder HITAP (Health Intervention and Technology Assessment Program)
Localising your Value Dossier - Pitfalls & Learnings from MEA	Lavni Varyani Founding Partner, Pharma Business Partners
Group case work	
Conclusion	

## Programme – Day 4 – Thu 29 Feb 2024

TOPICS	Speakers
Recap Day 3	
Advancing value-based pricing and procurement for a more value based healthcare (VBHC)	Arif Fahim Director Asia-Pacific, Health Economics & Reimbursement, Abbott Medical Devices
Korea: How to develop a comprehensive Market Access strategy in a developed HTA market	Sungwon Jung Director, Gov Affairs & Market Access, Baxter Korea
Reimbursement of Diagnostics : experience from the field in KR, JP, TW	Roche Diagnostics: Harry Peng (Taiwan) Norihisa Yamamoto (Japan) TBC
Digital Health Value Assessment and Reimbursement	Anh Bourcet
Group case work	
Conclusion	

#### Programme – Day 5 – Fri 1 Mar 2024

TOPICS	Speakers
Recap Day 4	
Market Access strategy for Niche Innovations	Alice Chu Senior Director, Market Access & Medical Affairs APAC, Glaukos
Group case presentation	Jury: Arif Fahim, Nordin Charafi, Anh Bourcet
Precision Medicine: towards an integrated Diagnostics & Treatment Access strategy ?	Nordin Charafi Director, Market Access, Asia Middle East & Africa, Illumina
Funding in Public Health	Global Fund (TBC)
Learnings & week in review	
Conclusion	